Graves’ disease is a rare autoimmune disorder that affects approximately 1 in 100 Americans and is the predominant cause of hyperthyroidism. Approximately 1 and 3 people suffering from Graves’ disease will develop thyroid eye disease (TED).
TED inflames the behind and surrounding the eyes. As tissue surrounding the eyes becomes further inflamed, it pushes the eyes forward, preventing an individual from being able to close them.
Without the protection of your eyelids to keep your eyes moist and free of debris, TED will cause redness, irritation, loss of vision, double vision, and changes in appearance. If not managed, this illness can cause permanent vision loss.
Typical treatments ointments, eye drops, and oral supplements. Surgical intervention may be necessary if traditional medications fail to treat the condition. However, your doctor may try prescribing you Tepezza to reduce your symptoms and manage your illness to prevent surgery.
Tepezza is a biological drug that is the first and only FDA-approved medication to treat thyroid eye disease.
Tepezza contains an active drug called insulin-like growth factor-1 receptor inhibitors. Tepezza works by binding to autoantibodies to prevent these dangerous molecules from triggering your immune system to attack your body.
At Pure Infusion Suites, we are experts at providing patients with a comfortable, patient-obsessed infusion experience. Our clinical model guarantees we never go above a 3:1 patient-to-nurse ratio. Each Pure Infusion Suite is equipped with a 55-inch flatscreen TV, WiFi access, comfortable recliners, and food and beverages catered to our patient’s desires.
The patient experience at Pure Infusion Suites is unparalleled compared to the industry standards, especially when it comes to reducing costs for payers and patients.
On Average, care at an ambulatory infusion center costs 53% less than infusion services offered at hospitals. We further increase affordability by offering co-pay assistance and other financial aid programs to our patients to lessen their burdens.